More recently, Baruch et al. [128] and Davar et al. [171] verified the efficacy of FMT in anti-PD-1 immunotherapy in patients with metastatic melanoma for the first time in a clinical trial. This evidence concerns the gene PDCD1 and metastatic melanoma.